ZFIN ID: ZDB-PUB-201123-10
PDE10A inhibition reduces the manifestation of pathology in DMD zebrafish and represses the genetic modifier PITPNA
Lambert, M.R., Spinazzola, J.M., Widrick, J.J., Pakula, A., Conner, J.R., Chin, J.E., Owens, J.M., Kunkel, L.M.
Date: 2020
Source: Molecular therapy : the journal of the American Society of Gene Therapy   29(3): 1086-1101 (Journal)
Registered Authors: Kunkel, Louis M.
Keywords: DMD, Genetic Modifier, PDE10A, Pathology, Pitpna, Therapy, Zebrafish
MeSH Terms: none
PubMed: 33221436 Full text @ Mol. Ther.
Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder caused by mutations in the DMD gene. Absence of dystrophin protein leads to progressive degradation of skeletal and cardiac function and leads to premature death. Over the years, zebrafish have been increasingly used for studying DMD and are a powerful tool for drug discovery and therapeutic development. In our study, a birefringence screening assay led to identification of PDE10A inhibitors that reduced the manifestation of dystrophic muscle phenotype in dystrophin-deficient sapje-like zebrafish larvae. PDE10A has been validated as a therapeutic target by pde10a morpholino-mediated reduction in muscle pathology and improvement in locomotion, muscle, and vascular function as well as long-term survival in sapje-like larvae. PDE10A inhibition in zebrafish and DMD patient-derived myoblasts were also associated with reduction of PITPNA expression that has been previously identified as a protective genetic modifier in two exceptional dystrophin-deficient GRMD dogs that escaped the dystrophic phenotype. The combination of a phenotypic assay and relevant functional assessments in the sapje-like zebrafish enhances the potential for the prospective discovery of DMD therapeutics. Indeed, our results suggest a new application for a PDE10A inhibitor as a potential DMD therapeutic to be investigated in a mouse model of DMD.